Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.

Takase M, Kimura H, Kanahara N, Nakata Y, Iyo M.

J Psychopharmacol. 2020 Jan 21:269881119900982. doi: 10.1177/0269881119900982. [Epub ahead of print]

PMID:
31961236
2.

A preliminary exome sequence in three patients with tardive dystonia.

Kanahara N, Nakata Y, Iyo M.

Psychiatr Genet. 2019 Dec 30. doi: 10.1097/YPG.0000000000000248. [Epub ahead of print]

PMID:
31895084
3.

Genetic combination risk for schizophrenia.

Oishi K, Niitsu T, Kanahara N, Hashimoto T, Komatsu H, Sasaki T, Takase M, Sato Y, Iyo M.

Schizophr Res. 2019 Aug 30. pii: S0920-9964(19)30376-7. doi: 10.1016/j.schres.2019.08.021. [Epub ahead of print] No abstract available.

PMID:
31477374
4.

Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia.

Kanahara N, Yoshimura K, Nakamura M, Oda Y, Watanabe M, Iyo M.

Int Clin Psychopharmacol. 2019 May;34(3):124-130. doi: 10.1097/YIC.0000000000000257.

PMID:
30870237
5.

Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.

Oishi K, Kanahara N, Takase M, Oda Y, Nakata Y, Niitsu T, Ishikawa M, Sato Y, Iyo M.

PLoS One. 2018 Nov 8;13(11):e0207133. doi: 10.1371/journal.pone.0207133. eCollection 2018.

6.

Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect.

Ikeda M, Takahashi A, Kamatani Y, Momozawa Y, Saito T, Kondo K, Shimasaki A, Kawase K, Sakusabe T, Iwayama Y, Toyota T, Wakuda T, Kikuchi M, Kanahara N, Yamamori H, Yasuda Y, Watanabe Y, Hoya S, Aleksic B, Kushima I, Arai H, Takaki M, Hattori K, Kunugi H, Okahisa Y, Ohnuma T, Ozaki N, Someya T, Hashimoto R, Yoshikawa T, Kubo M, Iwata N.

Schizophr Bull. 2019 Jun 18;45(4):824-834. doi: 10.1093/schbul/sby140.

PMID:
30285260
7.

First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort.

Kanahara N, Yamanaka H, Suzuki T, Takase M, Iyo M.

BMC Psychiatry. 2018 Sep 3;18(1):274. doi: 10.1186/s12888-018-1853-1.

8.

Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis.

Kanahara N, Hirabayashi M, Mamada T, Nishimoto M, Iyo M.

Schizophr Res. 2018 Dec;202:398-400. doi: 10.1016/j.schres.2018.06.038. Epub 2018 Jun 21. No abstract available.

PMID:
29937327
9.

Identifying improvable employment-related factors in schizophrenia patients.

Hasegawa T, Hashimoto T, Kanahara N, Yamanaka H, Ishige M, Sato Y, Iyo M.

Psychiatry Res. 2018 Aug;266:199-205. doi: 10.1016/j.psychres.2018.05.064. Epub 2018 May 28.

PMID:
29870957
10.

Association studies of WD repeat domain 3 and chitobiosyldiphosphodolichol beta-mannosyltransferase genes with schizophrenia in a Japanese population.

Kobayashi M, Jitoku D, Iwayama Y, Yamamoto N, Toyota T, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Kurumaji A, Yoshikawa T, Nishikawa T.

PLoS One. 2018 Jan 8;13(1):e0190991. doi: 10.1371/journal.pone.0190991. eCollection 2018.

11.

Genetic and molecular risk factors within the newly identified primate-specific exon of the SAP97/DLG1 gene in the 3q29 schizophrenia-associated locus.

Uezato A, Yamamoto N, Jitoku D, Haramo E, Hiraaki E, Iwayama Y, Toyota T, Umino M, Umino A, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Kurumaji A, Yoshikawa T, Nishikawa T.

Am J Med Genet B Neuropsychiatr Genet. 2017 Dec;174(8):798-807. doi: 10.1002/ajmg.b.32595. Epub 2017 Oct 9.

PMID:
28990294
12.

Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.

Nakata Y, Kanahara N, Iyo M.

J Psychopharmacol. 2017 Dec;31(12):1511-1518. doi: 10.1177/0269881117728428. Epub 2017 Sep 19. Review.

PMID:
28925317
13.

Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.

Oda Y, Fujita Y, Oishi K, Nakata Y, Takase M, Niitsu T, Kanahara N, Shirayama Y, Hashimoto K, Iyo M.

Psychopharmacology (Berl). 2017 Oct;234(20):3027-3036. doi: 10.1007/s00213-017-4695-5. Epub 2017 Jul 25.

PMID:
28744562
14.

Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.

Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M.

Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24. Review.

15.

The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.

Takase M, Kanahara N, Oda Y, Niitsu T, Watanabe H, Iyo M.

Schizophr Res. 2017 Dec;190:182-183. doi: 10.1016/j.schres.2017.03.014. Epub 2017 Mar 9. No abstract available.

PMID:
28285026
16.

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases.

Muneoka K, Kanahara N, Kimura S.

SAGE Open Med Case Rep. 2017 Feb 8;5:2050313X17692936. doi: 10.1177/2050313X17692936. eCollection 2017.

17.

Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population.

Saito T, Ikeda M, Hashimoto R, Iwata N; Members of the Clozapine Pharmacogenomics Consortium of Japan are the following, Yamamori H, Yasuda Y, Fujimoto M, Kondo K, Shimasaki A, Kawase K, Miyata M, Mushiroda T, Ozeki T, Kubo M, Fujita K, Kida N, Nakai M, Otsuru T, Fukuji Y, Murakami M, Mizuno K, Shiratsuchi T, Numata S, Ohmori T, Ueno SI, Yada Y, Tanaka S, Kishi Y, Takaki M, Mamoto A, Taniguchi N, Sawa Y, Watanabe H, Noda T, Amano Y, Kimura T, Fukao T, Suwa T, Murai T, Kubota M, Ueda K, Tabuse H, Kanahara N, Kawai N, Nemoto K, Makinodan M, Nishihata Y, Hashimoto N, Kusumi I, Fujii Y, Miyata R, Hirakawa K, Ozaki N.

Biol Psychiatry. 2017 Jul 1;82(1):e9-e10. doi: 10.1016/j.biopsych.2016.12.009. Epub 2016 Dec 16. No abstract available.

PMID:
28161127
18.

Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report.

Tadokoro S, Nonomura N, Kanahara N, Hashimoto K, Iyo M.

Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):79-81. doi: 10.9758/cpn.2017.15.1.79.

19.

Comprehensive association analysis of 27 genes from the GABAergic system in Japanese individuals affected with schizophrenia.

Balan S, Yamada K, Iwayama Y, Hashimoto T, Toyota T, Shimamoto C, Maekawa M, Takagai S, Wakuda T, Kameno Y, Kurita D, Yamada K, Kikuchi M, Hashimoto T, Kanahara N, Yoshikawa T.

Schizophr Res. 2017 Jul;185:33-40. doi: 10.1016/j.schres.2017.01.003. Epub 2017 Jan 7.

PMID:
28073605
20.

Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia.

Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M.

Int Clin Psychopharmacol. 2017 May;32(3):169-173. doi: 10.1097/YIC.0000000000000160.

PMID:
28067751
21.

Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.

Tachibana M, Niitsu T, Watanabe M, Hashimoto T, Kanahara N, Ishikawa M, Iyo M.

Asian J Psychiatr. 2016 Dec;24:28-32. doi: 10.1016/j.ajp.2016.08.014. Epub 2016 Aug 18.

PMID:
27931902
22.

Altered serum level of matrix metalloproteinase-9 and its association with decision-making in eating disorders.

Matsumoto J, Hirano Y, Hashimoto K, Ishima T, Kanahara N, Niitsu T, Shiina A, Hashimoto T, Sato Y, Yokote K, Murano S, Kimura H, Hosoda Y, Shimizu E, Iyo M, Nakazato M.

Psychiatry Clin Neurosci. 2017 Feb;71(2):124-134. doi: 10.1111/pcn.12490. Epub 2017 Jan 14.

23.

Increased Serum Levels of Oxytocin in 'Treatment Resistant Depression in Adolescents (TRDIA)' Group.

Sasaki T, Hashimoto K, Oda Y, Ishima T, Yakita M, Kurata T, Kunou M, Takahashi J, Kamata Y, Kimura A, Niitsu T, Komatsu H, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shimizu E, Iyo M.

PLoS One. 2016 Aug 18;11(8):e0160767. doi: 10.1371/journal.pone.0160767. eCollection 2016.

24.

Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.

Kimura H, Kanahara N, Sasaki T, Komatsu N, Ishige M, Muneoka K, Ino H, Yoshimura K, Yamanaka H, Suzuki T, Komatsu H, Watanabe H, Shimizu E, Iyo M.

J Psychopharmacol. 2016 Aug;30(8):795-802. doi: 10.1177/0269881116655978. Epub 2016 Jul 1.

PMID:
27371496
25.

A randomized, sham-controlled study of high frequency rTMS for auditory hallucination in schizophrenia.

Kimura H, Kanahara N, Takase M, Yoshida T, Watanabe H, Iyo M.

Psychiatry Res. 2016 Jul 30;241:190-4. doi: 10.1016/j.psychres.2016.04.119. Epub 2016 May 6.

PMID:
27179693
26.

Reply to "concern over your recent paper on risperidone long-acting injectable for treatment-resistant schizophrenia".

Kanahara N, Kimura H, Iyo M.

Schizophr Res. 2016 May;173(1-2):118. doi: 10.1016/j.schres.2016.03.004. Epub 2016 Mar 9. No abstract available.

PMID:
26971073
27.

Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population.

Saito T, Ikeda M, Mushiroda T, Ozeki T, Kondo K, Shimasaki A, Kawase K, Hashimoto S, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Takeda M, Kamatani Y, Numata S, Ohmori T, Ueno S, Makinodan M, Nishihata Y, Kubota M, Kimura T, Kanahara N, Hashimoto N, Fujita K, Nemoto K, Fukao T, Suwa T, Noda T, Yada Y, Takaki M, Kida N, Otsuru T, Murakami M, Takahashi A, Kubo M, Hashimoto R, Iwata N.

Biol Psychiatry. 2016 Oct 15;80(8):636-42. doi: 10.1016/j.biopsych.2015.12.006. Epub 2016 Feb 11.

28.

Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.

Yamanaka H, Kanahara N, Suzuki T, Takase M, Moriyama T, Watanabe H, Hirata T, Asano M, Iyo M.

Schizophr Res. 2016 Feb;170(2-3):252-8. doi: 10.1016/j.schres.2016.01.013. Epub 2016 Jan 13.

PMID:
26775264
30.

Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study.

Hashimoto T, Sakurai D, Oda Y, Hasegawa T, Kanahara N, Sasaki T, Komatsu H, Takahashi J, Oiwa T, Sekine Y, Watanabe H, Iyo M.

Neuropsychiatr Dis Treat. 2015 Dec 10;11:3031-40. doi: 10.2147/NDT.S95067. eCollection 2015.

31.

Increased serum levels of serine enantiomers in patients with depression.

Hashimoto K, Yoshida T, Ishikawa M, Fujita Y, Niitsu T, Nakazato M, Watanabe H, Sasaki T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M.

Acta Neuropsychiatr. 2016 Jun;28(3):173-8. doi: 10.1017/neu.2015.59. Epub 2015 Oct 29.

PMID:
26512905
32.

Repetitive Transcranial Magnetic Stimulation Changes Cerebral Oxygenation on the Left Dorsolateral Prefrontal Cortex in Bulimia Nervosa: A Near-Infrared Spectroscopy Pilot Study.

Sutoh C, Koga Y, Kimura H, Kanahara N, Numata N, Hirano Y, Matsuzawa D, Iyo M, Nakazato M, Shimizu E.

Eur Eat Disord Rev. 2016 Jan;24(1):83-8. doi: 10.1002/erv.2413. Epub 2015 Oct 20.

PMID:
26481583
33.

Population-dependent contribution of the major histocompatibility complex region to schizophrenia susceptibility.

Yamada K, Hattori E, Iwayama Y, Toyota T, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Mori N, Yoshikawa T.

Schizophr Res. 2015 Oct;168(1-2):444-9. doi: 10.1016/j.schres.2015.08.018. Epub 2015 Aug 29.

PMID:
26324334
34.

Erratum to: Association study of H2AFZ with schizophrenia in a Japanese case-control sample.

Jitoku D, Yamamoto N, Iwayama Y, Toyota T, Miyagi M, Enokida T, Tasaka Y, Umino M, Umino A, Uezato A, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Kurumaji A, Yoshikawa T, Nishikawa T.

J Neural Transm (Vienna). 2015 Nov;122(11):1619-20. doi: 10.1007/s00702-015-1429-x.

PMID:
26259709
35.

Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia.

Oda Y, Kanahara N, Kimura H, Watanabe H, Hashimoto K, Iyo M.

Neuropsychiatr Dis Treat. 2015 Jul 29;11:1845-51. doi: 10.2147/NDT.S86042. eCollection 2015.

36.

G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.

Oda Y, Tadokoro S, Takase M, Kanahara N, Watanabe H, Shirayama Y, Hashimoto K, Iyo M.

J Psychopharmacol. 2015 Dec;29(12):1308-13. doi: 10.1177/0269881115593903. Epub 2015 Jul 14.

PMID:
26174132
37.

Decreased levels of serum oxytocin in pediatric patients with Attention Deficit/Hyperactivity Disorder.

Sasaki T, Hashimoto K, Oda Y, Ishima T, Kurata T, Takahashi J, Kamata Y, Kimura H, Niitsu T, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M.

Psychiatry Res. 2015 Aug 30;228(3):746-51. doi: 10.1016/j.psychres.2015.05.029. Epub 2015 Jun 15.

38.

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, Yoshida T, Iyo M, Hashimoto K.

Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):62-7. doi: 10.9758/cpn.2015.13.1.62.

39.

Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.

Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, Iyo M.

Psychiatry Res. 2015 Jun 30;227(2-3):278-82. doi: 10.1016/j.psychres.2015.02.021. Epub 2015 Mar 31.

PMID:
25863824
40.

Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.

Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M.

J Psychopharmacol. 2015 Apr;29(4):383-9. doi: 10.1177/0269881115570083. Epub 2015 Mar 3.

41.

Genetic analysis of the glyoxalase system in schizophrenia.

Bangel FN, Yamada K, Arai M, Iwayama Y, Balan S, Toyota T, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Mori N, Itokawa M, Stork O, Yoshikawa T.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jun 3;59:105-110. doi: 10.1016/j.pnpbp.2015.01.014. Epub 2015 Jan 31.

PMID:
25645869
42.

Association study of H2AFZ with schizophrenia in a Japanese case-control sample.

Jitoku D, Yamamoto N, Iwayama Y, Toyota T, Miyagi M, Enokida T, Tasaka Y, Umino M, Umino A, Uezato A, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Kurumaji A, Yoshikawa T, Nishikawa T.

J Neural Transm (Vienna). 2015 Jun;122(6):915-23. doi: 10.1007/s00702-014-1332-x. Epub 2014 Nov 13. Erratum in: J Neural Transm (Vienna). 2015 Nov;122(11):1619-20.

PMID:
25392085
43.

Sequencing and expression analyses of the synaptic lipid raft adapter gene PAG1 in schizophrenia.

Balan S, Iwayama Y, Yamada K, Toyota T, Ohnishi T, Toyoshima M, Shimamoto C, Ide M, Iwata Y, Suzuki K, Kikuchi M, Hashimoto T, Kanahara N, Yoshikawa T, Maekawa M.

J Neural Transm (Vienna). 2015 Mar;122(3):477-85. doi: 10.1007/s00702-014-1269-0. Epub 2014 Jul 9.

PMID:
25005592
44.

Second-generation antipsychotics and bone turnover in schizophrenia.

Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, Yoshida T, Ishikawa M, Kimura H, Nomura F, Iyo M.

Schizophr Res. 2014 Aug;157(1-3):137-41. doi: 10.1016/j.schres.2014.05.009. Epub 2014 Jun 2.

PMID:
24888527
45.

Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study.

Sasaki T, Hashimoto K, Tachibana M, Kurata T, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M.

Neuropsychiatr Dis Treat. 2014 May 5;10:719-22. doi: 10.2147/NDT.S63075. eCollection 2014. No abstract available.

46.

A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.

Kimura H, Kanahara N, Komatsu N, Ishige M, Muneoka K, Yoshimura M, Yamanaka H, Suzuki T, Komatsu H, Sasaki T, Hashimoto T, Hasegawa T, Shiina A, Ishikawa M, Sekine Y, Shiraishi T, Watanabe H, Shimizu E, Hashimoto K, Iyo M.

Schizophr Res. 2014 May;155(1-3):52-8. doi: 10.1016/j.schres.2014.02.022. Epub 2014 Mar 23.

47.

Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study.

Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M.

Neuropsychiatr Dis Treat. 2014 Jan 24;10:147-51. doi: 10.2147/NDT.S58480. eCollection 2014.

48.

Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial.

Komatsu H, Sekine Y, Okamura N, Kanahara N, Okita K, Matsubara S, Hirata T, Komiyama T, Watanabe H, Minabe Y, Iyo M.

Schizophr Res. 2013 Oct;150(1):240-4. doi: 10.1016/j.schres.2013.08.007. Epub 2013 Aug 31.

49.

Onset Pattern and Long-Term Prognosis in Schizophrenia: 10-Year Longitudinal Follow-Up Study.

Kanahara N, Yoshida T, Oda Y, Yamanaka H, Moriyama T, Hayashi H, Shibuya T, Nagaushi Y, Sawa T, Sekine Y, Shimizu E, Asano M, Iyo M.

PLoS One. 2013 Jun 26;8(6):e67273. doi: 10.1371/journal.pone.0067273. Print 2013.

50.

Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.

Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H, Hashimoto K.

J Clin Psychopharmacol. 2013 Jun;33(3):398-404. doi: 10.1097/JCP.0b013e31828ea95c. Review.

PMID:
23609386

Supplemental Content

Loading ...
Support Center